PATENT CLAIM ANALYSIS

Application Number: 16083750
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-03
Patent Classification: ["514", "253070"]

Abstract:
Methods of using the antipsychotic drug aripiprazole in treating a neurodegenerative disease such as Machado-Joseph disease/Spinocerebellar ataxia type 3 (MJD/SCA3) are disclosed. The methods comprise administering aripiprazole in an amount effect to decrease protein aggregates in the central nervous system and intracellular forms of pathogenic proteins such as mutant ataxin-3.

Claim (Index 2):
The method of  claim 1 , wherein the subject has a neurodegenerative disease selected from the group consisting of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, spinocerebellar ataxia (SCA) type 1, SCA type 2, SCA type 6, SCA type 7, SCA type 17, Machado-Joseph disease/SCA type 3 (MJD/SCA3), Huntington's disease, dentatorubral pallidoluysian atrophy (DRPLA), and spinal and bulbar muscular atrophy, X-linked 1 (SBMA).

Metadata:
- Claim Count in Document: 36.0
- Percentile: 97.0
- Lexical Diversity: 1.17391
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14585607', '15761964', '15895877', '13936696', '15554679']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8094708581280023
- 35 USC 102 Novelty (BERT): 0.522445725237521
- Combined Prediction Score: 0.7807683448389543
- Mean Citation Score: 262.901052
- Max Citation Score: 323.41345
- Similarity Product: 226.3923990709007

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test